What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Miguel A. González-Gay focuses on Internal medicine, Immunology, Rheumatoid arthritis, Surgery and Giant cell arteritis.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
His Immunology study combines topics from a wide range of disciplines, such as Odds ratio, PTPN22, Single-nucleotide polymorphism, Genotype and Allele.
Miguel A. González-Gay has included themes like Arthritis, Infliximab, Endothelial dysfunction, Carotid ultrasonography and Intima-media thickness in his Rheumatoid arthritis study.
The study incorporates disciplines such as Anemia, Epidemiology and Cardiology in addition to Surgery.
His Giant cell arteritis research is multidisciplinary, incorporating elements of Dermatology and Arteritis.
His most cited work include:
- Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. (289 citations)
- Leptin in the interplay of inflammation, metabolism and immune system disorders (211 citations)
- High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. (211 citations)
What are the main themes of his work throughout his whole career to date?
Miguel A. González-Gay spends much of his time researching Internal medicine, Rheumatoid arthritis, Immunology, Gastroenterology and Disease.
Miguel A. González-Gay works mostly in the field of Internal medicine, limiting it down to concerns involving Surgery and, occasionally, Giant cell arteritis.
Miguel A. González-Gay interconnects Inflammation, Carotid ultrasonography and Cardiology, Endothelial dysfunction in the investigation of issues within Rheumatoid arthritis.
His research integrates issues of Genotype, Single-nucleotide polymorphism, Allele, Allele frequency and Vasculitis in his study of Immunology.
His Allele research integrates issues from Human leukocyte antigen and Locus.
His work in Gastroenterology addresses issues such as Adalimumab, which are connected to fields such as Uveitis.
He most often published in these fields:
- Internal medicine (58.93%)
- Rheumatoid arthritis (32.93%)
- Immunology (26.00%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (58.93%)
- Rheumatoid arthritis (32.93%)
- Gastroenterology (20.93%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Rheumatoid arthritis, Gastroenterology, Disease and Tocilizumab.
In his study, he carries out multidisciplinary Internal medicine and In patient research.
His research in Rheumatoid arthritis focuses on subjects like Diabetes mellitus, which are connected to Kidney disease.
In his study, Lipid profile is inextricably linked to Lipoprotein, which falls within the broad field of Gastroenterology.
He has researched Tocilizumab in several fields, including Refractory, Multicenter study, Infliximab, Giant cell arteritis and Prednisone.
The Infliximab study combines topics in areas such as Dermatology and Uveitis.
Between 2018 and 2021, his most popular works were:
- Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. (58 citations)
- Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. (52 citations)
- Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. (52 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
The scientist’s investigation covers issues in Internal medicine, Rheumatoid arthritis, Disease, Tocilizumab and Rheumatology.
Internal medicine is frequently linked to Gastroenterology in his study.
His Rheumatoid arthritis study combines topics in areas such as Arthritis, Autoimmune disease, Concordance, Proinflammatory cytokine and Intima-media thickness.
His Disease study combines topics in areas such as Radiology, Epidemiology and Retrospective cohort study.
His study in Tocilizumab is interdisciplinary in nature, drawing from both Anakinra, Refractory, Giant cell arteritis, Prednisone and Pediatrics.
His research integrates issues of Disease risk and Evidence-based medicine in his study of Rheumatology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
